SCHEMBL3882446

SCHEMBL3882446

CCCc1c(CC)ccc2cc(C(=O)Nc3ccc(CN)cc3)c(=O)oc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.51
MAOB P27338 1/20 0.51
MAPT P10636 4/20 0.49
TP53 P04637 1/20 0.49
S1PR1 P21453 5/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
POLB P06746 2/20 0.48
PLEC Q15149 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
PLG P00747 5/20 0.47
KLK1 P06870 5/20 0.47
KLK6 Q92876 4/20 0.47
AR P10275 1/20 0.46
AKR1C3 P42330 1/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
KDM4E B2RXH2 1/20 0.44
GAA P10253 1/20 0.44
HPGD P15428 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4510541 0.90 S1PR1 (0.51) MAOAMAOBMAPTTP53S1PR1
SCHEMBL4522924 0.88 MAOB (0.49) MAOAMAOBMAPTTP53S1PR1
SCHEMBL3880659 0.87 S1PR1 (0.65) MAOAMAOBMAPTTP53S1PR1
SCHEMBL3878298 0.87 PLG (0.47) MAOAMAOBMAPTTP53S1PR1
SCHEMBL4513642 0.87 S1PR1 (0.48) MAOAMAOBMAPTTP53S1PR1
SCHEMBL4521324 0.86 S1PR1 (0.54) MAOAMAOBMAPTTP53S1PR1
SCHEMBL3887100 0.85 S1PR1 (0.54) MAOAMAOBMAPTTP53S1PR1
SCHEMBL3881597 0.85 S1PR1 (0.54) MAOAMAOBMAPTTP53S1PR1
SCHEMBL3882855 0.84 S1PR1 (0.51) MAOAMAOBMAPTTP53S1PR1
SCHEMBL3946805 0.84 S1PR1 (0.52) MAOAMAOBMAPTTP53S1PR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090318546-A1 Chromen-2-One Derivatives NOVARTIS AG (CH) 2009-12-24 US claimed
EP-2010511-A1 CHROMEN-2-ONE DERIVATIVES Novartis AG (CH) 2009-01-07 EP claimed
WO-2007115820-A1 CHROMEN-2-ONE DERIVATIVES NOVARTIS AG (CH) 2007-10-18 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318546-A1 Chromen-2-One Derivatives CYP1A2, CYP4B1, CYP1B1 MAOA 1782/4885MAOB 1375/4885MAPT 3872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.